Place:
Online
Date:
5-7 October 2023
14:00
16th International Cardiovascular Research Meeting (ICVRM)
The ELECTRA-SIRIO 2 Investigators Meeting
Conference under the auspices of GREAT International Network
Bydgoszcz 5-7th October 2023
SCIENTIFIC PROGRAMME
We invite you to familiarize yourself with the details of the program.
14:00 - 14:10
Opening speech
Jacek Kubica (Poland)
14:10 - 14:30
Lecture of the day: Not Everything That Glitters is Gold, Even When Randomised
Marc P. Bonaca (USA)
14:30 - 15:45
Session 1
Chairpersons: Stefano De Servi, Eliano P. Navarese, Wojciech Wojakowski, Jacek Kubica
14:30 - 14:45
Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
Andrzej Budaj (Poland)
14:45 - 15:00
Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry
Stefan K James (Sweden)
15:00 - 15:15
Stepwise relationship between delay to percutaneous coronary intervention and long-term mortality in patients with non-ST-segment elevation myocardial infarction
Kamil Bujak (Poland)
15:15 - 15:30
GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromes
Holger Thiele (Germany)
15:30 - 15:45
Discussion
15:45 - 16:00
Break
16:00 - 17:15
Session 2
Chairpersons: Diana A. Gorog, Stefan K. James, Piotr Adamski
16:00 - 16:15
Should aspirin be stopped at day 0 after PCI?
Paul A Gurbel (USA)
16:15 - 16:30
Continue or discontinue aspirin before non-cardiac surgery?
Tobias Geisler (Germany)
16:30 - 16:45
Short DAPT for PCI after CABG: ready for prime time.
Jolanta M Siller-Matula (Austria)
16:45 - 17:00
Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field
Stefano De Servi (Italy)
17:00 - 17:15
Discussion
17:15 - 17:30
Break
17:30 - 18:45
Session 3
Chairpersons: Jolanta M. Siller-Matula, Tobias Geisler, Zuzana Motovska, Małgorzata Ostrowska
17:30 - 17:45
HeartLogic - a new research tool
Matteo Pavoni (Italy)
17:45 - 18:00
How to advance from translational researches to randomized clinical trials?: Experiences from the K-DAPT society
Young-Hoon Jeong (South Korea)
18:00 - 18:15
Effectiveness of lower maintenance dose of ticagrelor one month after myocardial infarction. The Randomized multicenter, international, double-blind Clinical Trial. Rationale, protocol and current status of the ELECTRA SIRIO 2 trial.
Jacek Kubica (Poland)
18:15 - 18:30
Comparison of de-escalation of DAPT intensity or duration in patients with ACS undergoing PCI
Diana A Gorog (United Kingdom)
18:30 - 18:45
Discussion
18:45 - 19:00
Break
19:00 - 20:15
Session 4
Chairpersons: Marianna Janion, Miłosz Jaguszewski, Katarzyna Mizia-Stec
19:00 - 19:15
Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study.
Marko Noc (Slovenia)
19:15 - 19:30
Dual antiplatelet therapy for shock patients with acute myocardial infarction (DAPT-SHOCK-AMI) trial
Zuzana Motovska (Czech Republic)
19:30 - 19:45
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
Bernd Jilma (Austria)
19:45 - 20:00
Cangrelor in high risk ST-segment elevation myocardial infarction patients treated with primary Percutaneous Coronary Interventions (CHRONOS PCI) study
Jacek Kubica (Poland)
20:00 - 20:15
Discussion
14:00 - 14:10
Summary of Day 1
Eliano P Navarese (Italy)
14:10 - 14:30
Lecture of the day: Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Nabil G Seidah (Canada)
14:30 - 15:45
Session 5
Chairpersons: Marianna Janion, Miłosz Jaguszewski, Piotr Adamski
14:30 - 14:45
Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study.
Eliano P. Navarese (Italy)
14:45 - 15:00
Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy - a subanalysis of the ODYSSEY APPRISE study
Maciej Banach (Poland)
15:00 - 15:15
Dietary management of patients at high risk for cardiovascular disease; EUROASPIRE V
Piotr Jankowski (Poland)
15:15 - 15:30
National Trends in Statin Use in Lithuania from 2010 to 2021
Jolita Badariene (Lithuania)
15:30 - 15:45
Discussion
15:45 - 16:00
Break
16:00 - 17:00
Session 6
Chairpersons: Wiktor Kuliczkowski, Marko Noc, Agnieszka Tycińska, Tomasz Fabiszak
16:00 - 16:15
Out-of-hospital cardiac arrest: Do we have to perform coronary angiography?
Wojciech Wańha (Poland)
16:15 - 16:30
Epidemiology, monitoring, and treatment strategy in cardiogenic shock. A multinational cross-sectional survey of ESC
Marek Gierlotka (Poland)
16:30 - 16:45
Pharmacokinetics, pharmacodynamic and repetitive use of levosimendan
Grzegorz Grześk (Poland)
16:45 - 17:00
Discussion
17:00 - 17:15
Break
17:15 - 18:15
Session 7
Chairpersons: Jarosław Kaźmierczak, Alberto Porcu, Łukasz Szarpak, Małgorzata Ostrowska
17:15 - 17:30
Impact of dual antiplatelet therapy duration on clinical outcome after coronary bifurcation stenting: results from the EuroBifurcation Club registry
Robert Gil (Poland)
17:30 - 17:45
Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada
Paolo Raggi (Canada)
17:45 - 18:00
Determinants of anti-SARS-CoV-2 antibodies after vaccination in kidney transplant recipients
Magdalena Krintus (Poland)
18:00 - 18:15
Discussion
18:15 - 18:30
Break
18:30 - 19:30
Session 8
Chairpersons: Piotr Jankowski, Maciej Lesiak, Sławomir Dobrzycki, Piotr Niezgoda
18:30 - 18:45
An update on novel therapies for treating patients with arterial thrombosis
Udaya S Tantry (USA)
18:45 - 19:00
COVID-19-induced coagulopathy - Experience, achievements, prospects.
Łukasz Szarpak (Poland)
19:00 - 19:15
Altered platelet reactivity, coagulation, endothelial and inflammatory markers early after smoking cessation
Bogumił Ramotowski (Poland)
19:15 - 19:30
Discussion
09:20 - 09:30
Summary of Day 2
Piotr Adamski (Poland)
09:30 - 10:30
Session 9
Chairpersons: Mariusz Gąsior, Salvatore Di Somma, Michał Kasprzak
09:30 - 09:45
Clinical Outcomes of Left Main Coronary Artery PCI With Rotational Atherectomy
Sławomir Dobrzycki
09:45 - 10:00
FLOzins for pREveNtion of Contrast inducEd nephropathy (FLORENCE) study. Rationale, protocol and current status of the FLORENCE study.
Piotr Niezgoda (Poland)
10:00 - 10:15
Coronary sinus reducer - an alternative for patients with refractory angina
Maciej Lesiak (Poland)
10:15 - 10:30
Discussion
10:30 - 10:45
Break
10:45 - 12:00
Session 10
Chairpersons: Jacek Kubica, Grzegorz Grześk, Bogumił Ramotowski
10:45 - 11:00
Dual antithrombotic therapy with Dabigatran and Ticagrelor in patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation undergoing percutaneous coronary intervention. Rationale, protocol and current status of the ADONIS trial.
Miłosz Jaguszewski (Poland)
11:00 - 11:15
Repetitive use of LEvosimendan in Ambulatory Heart Failure patients. Rationale, protocol and current status of the LEIA-HF trial.
Agnieszka Tycińska (Poland)
11:15 - 11:30
Clinical outcomes of left atrial appendage occlusion in patients with previous intracranial or gastrointestinal bleeding: Insights from the LOGIC International Multicenter Registry
Gavino Casu (Italy)
11:30 - 11:45
Myocardial Perfusion and Coronary Physiology Assessment of Microvascular Dysfunction in Patients Undergoing Transcatheter Aortic Valve Implantation-Rationale and Design
Wojciech Wojakowski (Poland)
11:45 - 12:00
Discussion
12:00 - 12:15
Break
12:15 - 13:30
Session 11: The ELECTRA-SIRIO 2 investigators’ standpoints
Chairpersons: Andrzej Budaj, Eliano P. Navarese
Panelists: Piotr Adamski, Sławomir Dobrzycki, Mariusz Gąsior, Marek Gierlotka, Grzegorz Grześk, Miłosz Jaguszewski, Marianna Janion, Adam Kern, Wacław Kochman, Aldona Kubica, Jacek Kubica, Wiktor Kuliczkowski, Maciej Lesiak, Grzegorz Sobieszek, Agnieszka Tycińska, Wojciech Wojakowski, Marzenna Zielińska
12:15 - 12:30
Bentracimab — a breakthrough for patients treated with antiplatelet agents?
Piotr Adamski
12:30 - 12:45
Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied?
Piotr Niezgoda
12:45 - 13:00
Extended antithrombotic therapy in patients with chronic coronary syndrome - which agent should be added to aspirin?
Małgorzata Ostrowska
13:00 - 13:15
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome.
Julia M. Umińska
13:15 - 13:30
Discussion
13:30 - 13:45
Break
13:45 - 15:00
Session 12: ELECTRA-SIRIO 2 trial investigators session
Chairpersons: Piotr Adamski, Miłosz Jaguszewski, Wiktor Kuliczkowski
Panelists: Tomasz Białoszyński, Bartosz Czarniak, Jacek Gessek, Łukasz Graczykowski, Paweł Grzelakowski, Tomasz Hajdukiewicz, Artur Klecha, Agata Kosobucka-Ozdoba, Bartosz Krakowiak, Ewa Laskowska, Lidia Manelska, Piotr Michalski, Łukasz Pietrzykowski, Ewa Obońska, Karolina Obońska, Maciej Piasecki, Przemysław Podhajski, Jakub Ratajczak, Janusz Romanek, Grzegorz Skonieczny, Mateusz Sobota, Paweł Szymański, Przemysław Wilczewski
13:45 - 14:45
ELECTRA-SIRIO 2 z perspektywy ABM
Marceli Ragan
ELECTRA-SIRIO 2 z perspektywy sponsora - CM UMK
Teresa Mallek-Urbańska
ELECTRA-SIRIO 2 z perspektywy CRO
Przemysław Magielski
ELECTRA-SIRIO 2 z perspektywy głównego badacza
Jacek Kubica
14:45 - 15:00
Discussion
15:00
Closing remarks
Jacek Kubica (Poland)
Files
INFARMA Certificate
Download
MAIN PARTNER
CONFERENCE SPONSORS
EDUCATIONAL GRANT
Photo gallery
Thank you for your attendance! Here we present some memories from the conference.
